Abstract
Between 1978 and 1983, 44 patients with advanced seminoma were treated with cis-platinum-based combination chemotherapy (39 patients) or with carboplatin (JM8), as a single agent (5 patients). Of the total group, 40 (90%) are alive and disease free. Two of the 4 patients who died relapsed as non-seminomatous germ-cell tumours. Results in previously untreated patients indicate that tumour volume is less important as a prognostic factor than in non-seminomas. Residual masses were present in almost 80% of patients 1 month after chemotherapy; such masses regress slowly and surgery is not indicated. Elective radiotherapy after chemotherapy appears to be inessential since relapse rates are comparable in irradiated (1/15) and unirradiated patients (1/16). Pretreatment serum HCG concentrations did not influence the outcome of chemotherapy. Preliminary results with JM8 suggest that it is an active single agent in the treatment of seminoma.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 24 print issues and online access
$259.00 per year
only $10.79 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Rights and permissions
About this article
Cite this article
Peckham, M., Horwich, A. & Hendry, W. Advanced seminoma: Treatment with cis-platinum-based combination chemotherapy or carboplatin (JM8). Br J Cancer 52, 7–13 (1985). https://doi.org/10.1038/bjc.1985.141
Issue Date:
DOI: https://doi.org/10.1038/bjc.1985.141
This article is cited by
-
Vielversprechendes Diagnostikum für urologische Tumoren
Uro-News (2014)
-
Oddball p53 in testicular tumors
Nature Medicine (1996)